In chondrosarcoma, the novel therapeutic strategies targeting AR signaling by monoclonal antibodies, soluble receptor protein, multikinase inhibitors, and RNA interference could serve as therapeutic agents for clinical application in humans. Here, AR is linked to chondrosarcoma.